Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
KCNS3 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9BQ31 |
|---|---|
| Clone Names | 110617194 |
| Gene ID | 3790 |
|---|---|
| Other Names | Potassium voltage-gated channel subfamily S member 3, Delayed-rectifier K(+) channel alpha subunit 3, Voltage-gated potassium channel subunit Kv93, KCNS3 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | KCNS3 |
|---|---|
| Function | Potassium channel subunit that does not form functional channels by itself. Can form functional heterotetrameric channels with KCNB1; modulates the delayed rectifier voltage-gated potassium channel activation and deactivation rates of KCNB1 (PubMed:10484328). Heterotetrameric channel activity formed with KCNB1 show increased current amplitude with the threshold for action potential activation shifted towards more negative values in hypoxic-treated pulmonary artery smooth muscle cells (By similarity). |
| Cellular Location | Cell membrane; Multi-pass membrane protein. Note=May not reach the plasma membrane but remain in an intracellular compartment in the absence of KCNB1 (PubMed:10484328). |
| Tissue Location | Detected in whole normal term placental and placental chorionic plate arteries and veins. Detected in syncytiotrophoblast and in blood vessel endothelium within intermediate villi and chorionic plate (at protein level) (PubMed:22943705) Detected in most tissues, but not in peripheral blood lymphocytes. The highest levels of expression are in lung (PubMed:10484328) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Voltage-gated potassium channels form the largest and mostdiversified class of ion channels and are present in both excitableand nonexcitable cells. Their main functions are associated withthe regulation of the resting membrane potential and the control ofthe shape and frequency of action potentials. The alpha subunitsare of 2 types: those that are functional by themselves and thosethat are electrically silent but capable of modulating the activityof specific functional alpha subunits. The protein encoded by thisgene is not functional by itself but can form heteromultimers withmember 1 and with member 2 (and possibly other members) of theShab-related subfamily of potassium voltage-gated channel proteins.This gene belongs to the S subfamily of the potassium channelfamily.
References
Nyholt, D.R., et al. Hum. Mol. Genet. 17(21):3318-3331(2008)van Es, M.A., et al. Nat. Genet. 40(1):29-31(2008)Schymick, J.C., et al. Lancet Neurol 6(4):322-328(2007)Gutman, G.A., et al. Pharmacol. Rev. 57(4):473-508(2005)Kerschensteiner, D., et al. Proc. Natl. Acad. Sci. U.S.A. 102(17):6160-6165(2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
